

Tyrosine hydroxylase lab 2010






Translational NeuroRecovery Lab 2019 - current






Block



Ischaemic stroke (embolic and

thrombotic)

Bleed



Haemorrhagic stroke

(subarachnoid and intracerebral)


1 in 4 of us will have a stroke


>13.7 million new strokes each year, and still increasing...

>80 million people living with stroke, and ~40% working age (under 60 years old)

~2/3 of stroke survivors will have some form of post-stroke complications, including cognitive impairment









Stroke-induced regional brain atrophy


- Wallerian degeneration
- **Neuroinflammation**




Photothrombotic stroke model

Motor and sensory regions of the cerebral cortex









Ong et al (2017) JCBFM Ong et al (2018) Stroke Bezanilla, Ong et al (2019) Exp Neurol

Aims:

ratio


To investigate the long-term functional consequences of cortical stroke


To explore the neuropathological changes (hippocampus)





Thiel and Heiss (2011) Stroke

































High incident of GH deficiency after stroke


Author, year	N	Characteristics	Time after stroke	GDH testing	Prevalence of GHD
Kreber et al. 2019	139	Age: 52 ± 0.91 Ischemic: 50%; Haemorrhagic 50%	≥ 3 months	Glucagon stimulation test	76/136 (54%)
Lillicrap, Ong et al. 2018	13	Age: 70 ± 7.61 (SD) Ischemic: 100% NIHSS: 11.08 ± 2.27 (SD)	4 – 10 days	GH releasing hormone + arginine	9/13 (69.2%)
Boehncke et al. 2011	46	Age: 61 ± 14.9 Ischemic: 100% NIHSS: 6 (1-15)*	66 – 274 days (128.2 ± 46)	GH releasing hormone + CRH	31/39 (79.5%)
Bondanelli et al. 2010	56	Age: 65 ± 1.3 Ischemic: 100% NIHSS: 10.75 ± 0.55	1 – 3 months (visit 1) and 12 – 15 months (visit 2)	GH releasing hormone + arginine	Visit 1: 17/56 (30.4%) Visit 2: 17/48 (35.4%) GHD was confirmed in 14 of 16 previous diagnosed cases, 3 newly diagnosed cases.
Bondanelli et al. 2006	42	Age: 67 ± 1.7 Ischemic: 100% NIHSS: 11.02 ± 0.87	19 – 209 days (61.7 ± 8.4)	GH releasing hormone + arginine	5/42 (11.9%)
See, Ong et al., under review					MONASH Wniversity











Summary

Stroke triggers a neurodegenerative condition

- · Neuronal death, neuroinflammation, accumulation of neurotoxic proteins
- · Post-stroke cognitive impairment

Therapeutic strategies to enhance the brain's endogenous capacity for neurorestorative processes after stroke

• Growth hormone treatment promotes neurogenesis and cognitive function



Acknowledgments







Prof Michael Nilsson Prof Rohan Walker Prof Jörgen Isgaard

Stroke Recovery Lab, the University of Newcastle

Students:

Dr Sonia Sanchez Bezanilla Dr Wei Zhen Chow Wen Xin See, Chen Xin Loh, Hui Wen Tee

Funding:

University of Newcastle
Hunter Medical Research Institute
Monash University Malaysia
IBRO-APRC Travel and Short Stay Grant
International Society for Neurochemistry















